Alexandria Pharmaceuticals results, Fiscal year 2021
Net profit, assets, equity and cash flow for Fiscal year 2021, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit117 millionEGP · −31.2% vs the same period a year earlier
Total assets793 millionEGP · −0.6% vs the same period a year earlier
Shareholders' equity586 millionEGP · +2.5% vs the same period a year earlier
Operating cash flow99.42 millionEGP · −28.9% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Fiscal year 2021 was about 117 million EGP, down −31.2% from 170 million EGP in Fiscal year 2020.
- Total assets at the end of Fiscal year 2021 were about 793 million EGP, and shareholders' equity about 586 million EGP.
- Operating cash flow for Fiscal year 2021 was positive at 99.42 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2020Change
Net profit117 million170 million−31.2%
Gross profit293 million344 million−14.8%
Total assets793 million799 million−0.6%
Total liabilities207 million227 million−8.5%
Shareholders' equity586 million572 million+2.5%
Total liabilities and equity793 million799 million−0.6%
Operating cash flow99.42 million140 million−28.9%
Investing cash flow-114 million-60.02 million−89.3%
Financing cash flow-100 million-78.08 million−28.4%
Net change in cash-114 million1.7 million−6827.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy